Interventional firm C.R. Bard has received Food and Drug Administration 510(k) clearance to market its Luminexx self-expanding nitinol biliary stent for the treatment of malignant biliary obstructions.
The Luminexx stent combines the trackability and flexibility of Bard's Memotherm Flexx biliary stent delivery system with the Luminexx stent's radiopaque marker technology, according to the Murray Hill, NJ-based firm. This technology greatly improves radiopacity, allowing for better stent visualization, pre- and post-placement, according to Bard. The Luminexx stent will be marketed through Bard's peripheral technologies division, and is available immediately.
By AuntMinnie.com staff writersMarch 6, 2001
Related Reading
Theragenics adds distributor, January 5, 2001
Bard taps Alpert for regulatory post, July 14, 2000
Copyright © 2001 AuntMinnie.com
